Detecting Ovarian Cancer Early; Allergy Med for NSCLC? Bad News for Anti-TIGIT Drug News, features, and commentary about cancer-related issues Dec 07, 2023
Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dish News, features, and commentary about cancer-related issues Dec 01, 2023
With an Old X-Ray, AI Can Detect High Risk of Lung Cancer in Never Smokers Tool could identify nonsmokers most likely to benefit from low-dose CT screening Nov 29, 2023
Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations Researchers suggest the drug is a promising option for this rare subgroup Nov 22, 2023
Reprogramming Tumors; Bad Stool Samples; Human Experiences in Cancer Care News, features, and commentary about cancer-related issues Nov 17, 2023
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer Drug achieved high response rates in TKI-naive and TKI-pretreated patients Nov 16, 2023
Lung Cancer Survival High at 20 Years With Screen-Detected Tumors After two decades, lung cancer-specific survival remained at 81% in I-ELCAP program Nov 07, 2023
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S. Findings suggest patients with SCLC are not screened for LEMS, despite their association Nov 02, 2023
ACS: Millions More Should Get Lung Cancer Screening Notably, new recommendations say it doesn't matter when a person quit smoking Nov 01, 2023
The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3 Oct 30, 2023 video
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC Amivantamab-based regimens improved oncologic outcomes, but with more side effects Oct 25, 2023
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer Adjuvant alectinib reduces disease-free survival hazard by 76% Oct 24, 2023
Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers Still some unanswered questions about benefit over other drug regimens, expert says Oct 24, 2023
Targeting KRAS in NSCLC: Recent Progress and New Approaches Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available Oct 23, 2023 video
New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
Pembrolizumab Wins FDA Approval in Operable Lung Cancer Checkpoint inhibitor demonstrated significant survival improvement in perioperative setting Oct 17, 2023
Hair Relaxers' Cancer Risk; Genetic Test Aids Rural Care; Drug Negotiation Fallout? News, features, and commentary about cancer-related issues Oct 13, 2023
New Lung Cancer Cases Are Higher in Younger Women vs Men And the higher incidence rates now extend to women ages 50 to 54 as well Oct 12, 2023
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients Oct 12, 2023
Primary Care Intervention Improved Follow-Up of Abnormal Cancer Screening Results Follow-up testing within 120 days was improved with EHR reminders, patient outreach, navigation Oct 10, 2023
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Live News, features, and commentary about cancer-related issues Oct 06, 2023
Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel But聽agency doesn't plan to immediately push for KRAS inhibitor's withdrawal Oct 05, 2023
Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? Detectable circulating tumor DNA before radiotherapy linked with worse survival Oct 05, 2023
Drugmaker Plans to Pull Lung Cancer Therapy From the Market Randomized trial of mobocertinib (Exkivity) failed to confirm聽benefit in rare tumor type Oct 04, 2023
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC Reviewers see potentially tiny PFS benefit with sotorasib, raise concerns over "systemic bias" Oct 04, 2023
Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancer Combination may "provide meaningful antitumor activity," researchers say Sep 28, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
The White House Cancer Moonshot Is a Dud We're failing to take simple steps to reduce one of the biggest causes of cancer Sep 22, 2023
TikTok Dinged for Misinformation; BRCA Risk Overestimated; Cheers for Oncology News, features, and commentary about cancer-related issues Sep 21, 2023
Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancer Threefold risk reduction with enoxaparin in high-risk gastrointestinal, lung cancers Sep 21, 2023
Cisplatin Shortage Eases; Air Pollution Linked to Breast Cancer; Pap Test Confusion News, features, and commentary about cancer-related issues Sep 15, 2023
Individualized SABR for Lung Tumors Yields Low Recurrence Rates Strategy also results in low rates of severe toxic effects Sep 14, 2023
IMRT Best for Locally Advanced NSCLC, Study Suggests Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT Sep 13, 2023
Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC Confirmed responses reached 29.8% in heavily pretreated patients Sep 13, 2023
Study Questions Use of Aggressive Surgery in Early Mesothelioma Randomized data suggest surgery increases risk of death by 28% over first 42 months Sep 12, 2023
Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone Sep 12, 2023
First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
How the Chemotherapy Shortage Is Affecting Frontline Clinicians "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
